RT Journal Article
SR Electronic
T1 Efficacy and Safety of Monthly Minodronate Therapy in Postmenopausal Breast Cancer Patients Receiving Aromatase Inhibitors
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4139
OP 4143
DO 10.21873/anticanres.15912
VO 42
IS 8
A1 OGATA, NANAE
A1 TOH, UHI
A1 SUDOU, TOMOYA
A1 OGATA, SUGURU
A1 TAKAO, YUKO
A1 SUGIHARA, RIE
A1 WATANABE, HIDEAKI
A1 MATUSHIMA, SHUNTARO
A1 AKAGI, YOSHITO
YR 2022
UL http://ar.iiarjournals.org/content/42/8/4139.abstract
AB Background/Aim: Post-menopausal breast cancer (BC) patients who receive adjuvant aromatase inhibitor (AI) therapy may be at increased risk of bone loss, osteoporosis, and bone fracture. We aimed to evaluate the efficacy and safety of oral bisphosphonate minodronate in preventing bone loss complications. Patients and Methods: Patients receiving AI and 80% of those with suboptimal bone mineral density (BMD) were prescribed monthly oral minodronate 50 mg every 4 weeks for 72 weeks. BMD, bone metabolism markers, incidence of bone fractures, medication compliance, and other adverse events (AE) were examined every 24 weeks following administration. Results: Fifty postmenopausal BC patients with a median age of 64.0 years were enrolled. The mean value of lumbar spine BMD was higher than that of the value before the minodronate administration at each observation point. Before and after the treatment, the median serum values of Tartrate-resistant Acid Phosphatase 5b (TRACP-5b) (mU/dl) and serum type I collagen cross-linked N-telopeptide (NTX) (nmolBCE/l) were decreased from 535.7 and 18.5 to 230.1 and 11.9, respectively. No adverse grade 2 or higher event was observed throughout this study. Conclusion: The combined administration of minodronate and AIs was safe and effective in preventing bone loss complications in postmenopausal BC patients.